Corcept Therapeutics (CORT) Tops Q2 EPS by 35c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.86 -2.07%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
NSLR, OCTV, ACB, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
NSLR, OCTV, ACB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $256.1 million versus the consensus estimate of $217.85 million.
FY 2026 Outlook:-
Revenue between $1.1 billion – $1.2 billion vs consensus $999.5 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
- Canterbury Park (CPHC) Misses Q2 EPS by 3c
- William Blair Downgrades Cardiff Oncology (CRDF) to Market Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
